Conclusion
CSVT is an important complication of ALL treatment, especially in areas where its incidence is reported to be high as in Lebanon. Some risk factors have been previously identified and our study was able to augment with novel and additional risk factors that have not been previously discussed (Triglyceride level > 615 mg/dL, mediastinal mass and body surface area in multivariate analysis). Given the poor literature and recommendation consensus in relation to CSVT prophylaxis and the newly unveiled risk factors that are highlighted in our study, we recommend further prospective studies with larger samples to confirm our findings and help identify the subgroup of patients that qualify for CSVT prophylaxis during ALL treatment.